Alice Melao,  —

Edsivo (celiprolol), being developed by Acer Therapeutics, is one step closer to approval for the treatment of vascular Ehlers-Danlos syndrome (vEDS), as the U.S. Food and Drug Administration (FDA) agreed to review the new drug application (NDA) for the therapy. The regulatory agency also granted priority…

A multidisciplinary pain program, which includes medication and self-management strategies, helps patients with Ehlers-Danlos syndrome cope with chronic pain and improve their daily lives, two case reports show. The study, “Pain management in the Ehlers-Danlos syndromes,” was published in the American Journal…

October has been designated as the month to increase awareness on dysautonomia, a complex group of diseases caused by abnormalities in the autonomic nervous system that can also affect patients with Ehlers-Danlos syndrome. Throughout the month, Dysautonomia International is promoting several events to raise awareness and enhance patient advocacy…

Early recognition of patients affected by Ehlers-Danlos syndrome (EDS) is important to prevent painful complications of the disease that can limit daily life activities, researchers suggest in a case report. The report, “Ehlers–Danlos Syndrome: Not Just Joint Hypermobility,” highlights the importance of early diagnosis for a…

A case of vascular Ehlers-Danlos syndrome (vEDS) which appeared as a rapidly growing neck mass was reported by researchers at the University of California San Francisco (UCSF) Medical Center. The case was described in the study, “Vascular Ehlers-Danlos Syndrome Presenting as a Pulsatile Neck Mass: a…

A type of abnormal communication between the main blood vessels in the head, called carotid-cavernous fistula, may be the first manifestation of vascular Ehlers-Danlos syndrome (vEDS) among seemingly healthy young individuals, researchers reported in a recent study. The study, “Pathophysiology of carotid-cavernous fistulas in vascular Ehlers-Danlos…

Acer Therapeutics is planning to request approval for its investigative therapy Edsivo (celiprolol) to treat patients with vascular Ehlers-Danlos syndrome (vEDS) in the United States. The company expects to submit a new drug application (NDA) to the U.S. Food and Drug Administration by the end of the first…